Browse > Article

Changes of Lipid and Lipoprotein Compositions in Kawasaki Disease and its Impact on Cardiac Complications  

Yun, Sin Weon (Department of Pediatrics, College of Medicine, Chung-Ang University)
Lee, Ho Seok (Department of Pediatrics, College of Medicine, Chung-Ang University)
Kim, Dong Woon (Department of Pediatrics, College of Medicine, Chung-Ang University)
Rhee, Kang Won (Department of Pediatrics, College of Medicine, Chung-Ang University)
Jung, Young Soo (Department of Pediatrics, College of Medicine, Chung-Ang University)
Publication Information
Clinical and Experimental Pediatrics / v.48, no.12, 2005 , pp. 1370-1377 More about this Journal
Abstract
Purpose : Delineation of serum lipid and lipoprotein values in children after Kawasaki disease(KD) is important because of the predilection of this disease for the coronary arteries. Methods : The KD group was composed of 51 patients who were hospitalized from Jan. 2002 to Dec. 2003. Control was 25 patients with non-KD febrile illness. The levels of total lipid, phospholipid, triglyceride, HDL-cholesterol(HDL-C), LDL-cholesterol, total cholesterol, apolipoprotein A1(apo A1), apolipoprotein B, and Lipoprotein(a) were measured and compared with Echocardiographic findings. Measurements were obtained in four time periods: acute febrile, subacute, convalescent phase and 1 year after KD. Results : HDL-C($33.64{\pm}7.49mg/dL$ vs $50.43{\pm}14.41mg/dL$, P<0.01) and apo A1($99.75{\pm}6.39mg/dL$ vs $113.34{\pm}11.35mg/dL$, P<0.05) were decreased more in the acute febrile period of KD than in the control, but these changes were not correlated with cardiac complications. All lipid profiles were markedly elevated in the subacute stage and normalized in the convalescent stage; there were no changes until 1-year follow up. There were no significant differences in the changes of lipid profiles, including Lp(a) and coronary dilatation, in any time periods. Conclusion : KD is associated with important abnormalities in lipid metabolism, but these changes were transient and appear to be due to the disease itself. These data lead us to infer that KD dose not cause such permanent changes in lipid abnormalities as to be considered a risk factor for atherosclerosis, beyond that caused by the disease itself.
Keywords
Kawasaki disease; HDL cholesterol; Apolipoprotein A-1; Lipoprotein(a);
Citations & Related Records
연도 인용수 순위
  • Reference
1 Choi SM, Choi JH. Levels of serum HDL-cholesterol and total cholesterol in Kawasaki disease and their significance. Korean Circ J 1997;27:1298-302   DOI
2 Stein EA, Myers G. Lipid, apolipoproteins, and lipoproteins In : Burtis CA, Ashwood ER. Trietz fundamentals of clinical chemistry. 4th ed. Philadelphia : WB Saunders, 1996:375-401
3 Kurotobi S, Nagai T, Kawakami N, Sano T. Coronary diameter in normal infants, children and patients with Kawasaki disease. Pediatr int 2002;44:1-4   DOI   ScienceOn
4 Cabana VG, Gidding SS, Getz GS, Chapman J, Shulman ST. Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res 1997;42:651-5   DOI   ScienceOn
5 Salo E, Pesonen E, Viikari J. Serum cholesterol levels during and after kawasak disease. J Pediatr 1991;119:557-61   DOI   PUBMED
6 Chenaud C, Merlani PG, Roux-Lombard P, Burger D, Harbarth S, Luyasu S, et al. Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation Crit Care Med 2004;32: 632-7   DOI   ScienceOn
7 Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, et al. Low lipid concentrations in critical illness : Implications for preventing and treating endotoxemia. Crit Care Med 1996;24:584-9   DOI   ScienceOn
8 Suzuki A, Miyagawa-Tomita S, Komatsu K, Nishikawa T, Sakomura Y, Horie T, et al. Active Remodeling of the coronary arterial lesions in the late phase of Kawasaki disease immunohistochemical study. Circulation 2000;101:2935-41   DOI   ScienceOn
9 Hsieh KS, Weng KP, Lin CC, Hwang DC, Liu WS, Chen FL. The serial change of serum lipid profile in Kawasaki disease. Chest 1997;112:66S
10 Kawasaki T. Acute febrile mucocutaneous lymph node syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Jpn J allergy 1967;16:178-222
11 Fahie-Wilson M, Mills R, Wilson K. HDL cholesterol and the acute phase reaction following myocardial infarction and acute pancreatitis. Clin Chim Acta 1987;167:197-209   DOI   ScienceOn
12 Pajkrt D, Manten A, van der Poll T, Tiel-van Buul MM, Jansen J, Wouter ten Cate J, et al. Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 1997; 90:1415-24
13 Newburger JW. Kawasaki disease : Who is at risk? (Editorial) J Pediatr 2000;137:149-52   DOI   PUBMED   ScienceOn
14 Chiang AN, Hwang B, Shaw GC, Lee BC, Lu JH, Meng CCL, et al. Changes in plasma level of lipids and lipoprotein composition in patients aith Kawasaki disease. Clinic Chimica Acta 1997;260:15-26   DOI   ScienceOn
15 Marcovina SM, Koschinsky ML. A critical evaluation of the role of Lp(a) in cardiovascular disease : Can Lp(a) be useful in risk assessment? Semin Vasc Med 2002;2:335-44   DOI   ScienceOn
16 Lee YJ, Lee YS, Hyun MC, Lee SB. Lipid profile changes in Kawasaki disease patients. J Korean Pediatr Soc 2000; 43:216-22
17 Silva AA, Maeno Y, Hasbmi A, Smallborn JF, Silverman ED, McCrindle BW. Cardiovascular risk factors after Kawasaki disease a case-control study. J Pediatr 2001;138: 400-5   DOI   ScienceOn
18 Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK, Roux-Lombard P, et al. Apolipoprotein A-I inhibits the production of interleukin-1 and tumor necrosis factor alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001;97:2381-9   DOI   PUBMED   ScienceOn
19 Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the national heart, lung, and blood institute workshop on Lipoprotein(a) and cardiovascular disease: Recent advances and future directions. Clin Chem 2003;49: 1785-96   DOI   ScienceOn
20 Noto N, Okada T, Yamasuge M, Taniguchi K, Karasawa K, Ayusawa M, et al. Noninvasive assessment of the early progression of atherosclerosis in adolescents with Kawasaki disease and coronary artery lesions. Pediatrics 2001;107: 1095-9   DOI   PUBMED   ScienceOn
21 Okada T, Harada K, Okuni M. Serum HDL-cholesterol and lipoprotein fraction in Kawasaki disease(acute mucocutaneous lymphnode syndrome). Jpn Circ J 1982;46:1039-42   DOI   ScienceOn
22 Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation 1991;84: 625-31   DOI   ScienceOn
23 Van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003;31:1359-66   DOI   ScienceOn
24 Senzaki H, Chen CH, Ishido H, Masutani S, Matsunaga T, Taketazu M, et al. Arterial hemodynamics in patients after Kawasaki disease. Circulation 2005;111:2119-25   DOI   ScienceOn
25 Cheung YF, Yung TC, Tam SC, Ho MH, Chau AK. Novel and traditional cardiovascular risk factors in children after Kawasaki disease. Implications for premature atherosclerosis. J Am Coll Cardiol 2004;43:120-4   DOI   ScienceOn
26 Berg K. Immunochemical studies of the Lp(a) factor. Acta Pathol Microbiol Scand 1964;62:600-12   DOI
27 Dhillon R, Clarkson P, Donald AE, Powe AJ,Nash M, Novelli V, Dillon MJ, Deanfield JE. Endothelial dysfunction late after Kawasaki disease. Circulation 1996;94:2103-6   DOI   ScienceOn
28 Fraunberger P, Nagel D, Walli AK, Seidel D, Walli K, Seidel D. Serum cholesterol and mortality in patients with multiple organ failure. Crit Care Med 2000;28:3574-5   DOI   ScienceOn
29 McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein( a) is homologous to plasminogen. Nature 1987;330: 132-7   DOI   ScienceOn